Sanofi sharpens focus on bispecifics, and China, with Alphamab deal

Sanofi sharpens focus on bispecifics, and China, with Alphamab deal

Source: 
Endpoints
snippet: 

It’s not the splashy acquisition Sanofi was expected to make after pocketing more than $11 billion following the sale of a big chunk of partner Regeneron’s stock, but it’s a start. On Tuesday, the company signed a pact with China’s Alphamab Oncology to collaborate on a bispecific antibody focused on treating breast cancer.